BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance

What This Product Solves

BFH772 (SKU B6199) is a small-molecule VEGFR2 inhibitor with high potency and selectivity, specifically designed for research applications targeting the VEGFR2 signaling pathway. Its primary utility is in modulating angiogenesis in experimental tumor models where off-target kinase inhibition must be minimized. With an IC50 of 3 nM for VEGFR2 and markedly reduced activity against related kinases, BFH772 provides researchers with a tool for precise pathway interrogation without the confounding effects of non-VEGFR2 inhibition (source: product_spec). It addresses the need for dependable, selective inhibition in workflows where VEGFR2-driven angiogenesis is a focal research objective and is not intended for settings requiring water solubility or broad inhibition profiles.

Protocol Parameters

• VEGFR2 kinase inhibition assay | 3 nM (IC50) | Suitable for high-sensitivity kinase activity studies and angiogenesis assays | High potency allows for low compound concentrations and reduces off-target effects | product_spec (link)
• Compound solubility in DMSO | ≥53.4 mg/mL | Applicable to workflows requiring high-concentration stock solutions in DMSO | Ensures preparation of concentrated stocks for in vitro and in vivo use; facilitates serial dilutions | product_spec
• Storage temperature | -20°C | Required for maintaining compound stability during storage | Prevents degradation of BFH772 and preserves analytical purity | product_spec
• Solubility in ethanol | ≥15.33 mg/mL | For workflows compatible with ethanol as a vehicle | Allows flexibility in formulation when DMSO is not preferred; not suitable for water-based systems | product_spec
• Recommended use in organic solvent-based assays | Workflow-specific | Applicable to cellular and biochemical assays requiring organic solvent vehicles | BFH772 is insoluble in water; water-based applications are not supported | workflow_recommendation (internal_article)

Workflow Setup and QC Checklist

• Compound Handling: Obtain BFH772 as provided by APExBIO with purity >96%, accompanied by certificate of analysis and safety data sheet.
• Stock Preparation: Dissolve in DMSO or ethanol at the recommended concentrations. Confirm complete dissolution by visual inspection; do not attempt dissolution in water.
• Aliquoting: Prepare small aliquots to avoid multiple freeze-thaw cycles. Use amber vials if possible to minimize light exposure.
• Storage: Store powder and solutions at -20°C. Avoid long-term storage of solutions; prepare fresh working solutions as needed.
• Quality Control: Verify batch purity and molecular weight (439.39 g/mol) using provided documentation. Ensure all lab personnel are familiar with the safety data sheet.
• Vehicle Control: Always include appropriate DMSO or ethanol vehicle controls to account for solvent effects in biological assays.
• Documentation: Record lot numbers, preparation dates, and storage conditions for traceability.

For further procedural details on solubility and selectivity, see this internal technical article, which explains the importance of organic solvent compatibility and high kinase selectivity for reliable angiogenesis research.

Common Failure Modes and Fixes

• Poor compound solubility: If BFH772 does not fully dissolve, verify solvent freshness and temperature. Warm gently (< 40°C) and vortex; do not use water as a solvent.
• Precipitation during dilution: To avoid precipitation, dilute stock solutions slowly into pre-warmed assay buffer containing at least 0.1% DMSO or ethanol, ensuring the final solvent concentration is compatible with cell viability.
• Loss of activity in solution: Only prepare working solutions immediately prior to use. Discard any unused solutions after use rather than storing long-term, as stability in solution is not guaranteed (source: product_spec).
• Inconsistent biological response: Confirm batch identity and purity, and verify that VEGFR2-driven pathways are the primary angiogenesis mechanism in your model. For workflows requiring broad-spectrum kinase inhibition, consider alternative agents (see protocol guidance for further discussion).

Scope and Limitations

• Intended Use: BFH772 is intended for research use as a VEGFR2 signaling pathway inhibitor and anti-angiogenic agent in models where specificity for VEGFR2 is required.
• Solubility Constraints: The compound is insoluble in water; unsuitable for protocols requiring aqueous vehicles or administration.
• Kinase Selectivity: Not appropriate for studies demanding broad-spectrum kinase inhibition; selectivity profile restricts use to VEGFR2-centric applications (source: product_spec).
• Clinical/Translational Use: While advanced to clinical studies for rosacea, BFH772 is provided for research use only and must not be used in clinical or diagnostic workflows.

Conclusion

BFH772 (VEGFR2 inhibitor) offers a robust solution for researchers requiring targeted inhibition of VEGFR2-mediated angiogenesis in tumor and angiogenic model systems. Its high potency, selectivity, and defined solubility profile support reproducible results in workflows compatible with organic solvents. Researchers should avoid water-based protocols and broad-spectrum kinase studies with this compound. For full technical specifications and ordering information, refer to the BFH772 (VEGFR2 inhibitor) product page.